The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AngioDynamics's revenues will grow 60.9% and EPS will compress -44.4%.
The average estimate for revenue is $83.0 million. On the bottom line, the average EPS estimate is $0.05.
Last quarter, AngioDynamics booked revenue of $87.0 million. GAAP reported sales were 50% higher than the prior-year quarter's $58.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.10. GAAP EPS of $0.06 for Q2 were 33% lower than the prior-year quarter's $0.09 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 50.7%, 650 basis points worse than the prior-year quarter. Operating margin was 8.1%, 80 basis points worse than the prior-year quarter. Net margin was 2.3%, 170 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $340.9 million. The average EPS estimate is $0.33.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 99 members out of 114 rating the stock outperform, and 15 members rating it underperform. Among 31 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give AngioDynamics a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AngioDynamics is outperform, with an average price target of $13.50.
Is AngioDynamics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add AngioDynamics to My Watchlist.